BiomX Inc. 8-K

What Happened

• On June 10, 2026, NYSE Regulation accepted BiomX Inc.'s plan to regain compliance with NYSE American continued listing standards and granted a plan period through September 25, 2027. The Company had earlier received a March 25, 2026 notice that it was not in compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide due to a reported stockholders’ deficit of $(1,302,000) as of December 31, 2025 and losses over the past five fiscal years. During the plan period, BiomX’s common stock will remain listed and traded on NYSE American, but a “.BC” (below compliance) indicator will be attached to its ticker and the company will be listed among noncompliant issuers. The Company issued a press release about the plan acceptance on June 12, 2026 (furnished as Exhibit 99.1).

Key Details

• NYSE acceptance date: June 10, 2026; plan period ends: September 25, 2027.
• Cause of noncompliance: stockholders’ deficit of $(1,302,000) as of Dec 31, 2025 and multi-year losses.
• Trading status: shares continue to trade on NYSE American with a “.BC” (below compliance) indicator; company appears on Exchange’s noncompliant issuers list.
• Next steps: if the Company does not regain compliance or make satisfactory progress by the plan deadline, NYSE Regulation may initiate delisting proceedings.

Why It Matters

• For investors, the acceptance of a compliance plan means the stock remains tradable for now, but the “below compliance” tag signals elevated risk and may affect liquidity and share price. The company faces a defined deadline (Sept 25, 2027) to restore required stockholders’ equity levels or demonstrate sufficient progress. BiomX stated it will use reasonable efforts to regain compliance but provided no assurance it will succeed, so shareholders should monitor future filings and announcements for remediation actions (capital raises, restructuring, or other measures) and any material updates from NYSE Regulation.